Back to News
Market Impact: 0.28
XORTX Begins Clinical, Commercial Manufacturing Of XORLO For Gout Program; Shares Surge To 31%
Source: Nasdaq
Healthcare & BiotechProduct Launches
XORTX Therapeutics began drug-substance production and tablet manufacturing for XORLO, its gout-treatment candidate, to support the planned two-part XRX-OX clinical program. The manufacturing start represents a positive development milestone for the late-stage biotech and lifted shares in overnight trading, though clinical and regulatory execution risks remain.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
XRTX0.58
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Apple says it will replace iPhone Duo units showing screen problems
- Bank of England reviews Revolut’s product approval controls - report
- Apple responds to user reports of broken iPhone Duo screens on new foldable phone
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Uh oh, it sounds like the iPhone Duo keeps cracking and users aren’t happy about it